A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer

Trial Profile

A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Ribociclib (Primary) ; Aromatase inhibitors
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jun 2018 Planned End Date changed from 1 May 2020 to 1 Jun 2020.
    • 20 Jun 2018 Planned primary completion date changed from 1 May 2020 to 1 Jun 2020.
    • 20 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top